Status:
COMPLETED
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive...
Eligibility Criteria
Inclusion
- Patient is able to provide written informed consent before beginning any study related procedures
- Patient has a documented clinical diagnosis of major depressive disorder
- Patient is able to understand and comply with the requirements of the study, as judged by a study investigator
Exclusion
- Patients with a history of non-compliance as judged by the study investigator
- Patients with a known lack of response to previous treatment with quetiapine
- Patients who have participated in a clinical trial within 4 weeks of randomization
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT00326144
Start Date
April 1 2006
End Date
May 1 2007
Last Update
March 25 2009
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States
2
Research Site
Little Rock, Arkansas, United States
3
Research Site
Anaheim, California, United States
4
Research Site
El Centro, California, United States